Randomised controlled trials and population-based observational research: Partners in the evolution of medical evidence

British Journal of Cancer

Volumn 110, Issue 3, 2014, Pages 551-555

  Booth, C M ^a   Tannock, I F ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

clinical trials; effectiveness; efficacy; observational research; outcomes; quality of care

Indexed keywords

COST-BENEFIT ANALYSIS; HUMANS; NEOPLASMS; QUALITY OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84893757599     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.725     Document Type: Note

References (62)

1. Altwairgi AK, Booth CM, Hopman WM, Baetz TD (2012) Discordance between conclusions stated in the abstract and conclusions in the article: analysis of published randomized controlled trials of systemic therapy in lung cancer. J Clin Oncol 30: 3552-3557.
2. Bach PB, Cramer LD, Warren JL, Begg CB (1999) Racial differences in the treatment of early-stage lung cancer. N Engl J Med 341: 1198-1205.
3. Baxter NN, Virnig BA, Durham SB, Tuttle TM (2004) Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 96: 443-448.
4. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346: 1128-1137.
5. Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK (2008) Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol 26: 5458-5464.
6. Booth CM, Le MA, Ding K, Farn K, Fralick M, Phillips C, Cescon DW, Meyer RM (2009a) Presentation of nonfinal results of randomized controlled trials at major oncology meetings. J Clin Oncol 27: 3938-3944.
7. Booth CM, Ohorodnyk P, Eisenhauer EA (2009b) Call for clarity in the reporting of benefit associated with anticancer therapies. J Clin Oncol 27: e213-e214.
8. Booth CM, Shepherd FA, Peng Y, Darling GE, Li G, Kong W, Mackillop WJ (2010) Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. J Clin Oncol 28: 3472-3478.
9. Boutron I, Dutton S, Ravaud P, Altman DG (2010) Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303: 2058-2064.
10. Boyd C, Zhang-Salomons JY, Groome PA, Mackillop WJ (1999) Associations between community income and cancer survival in Ontario, Canada, and the United States. J Clin Oncol 17: 2244-2255.
11. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29: 4294-4301.
12. Chen SL, Bilchik AJ (2006) More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 244: 602-610.
13. Concato J (2012) Is it time for medicine-based evidence? JAMA 307: 1641-1643.
14. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28: 1117-1123.
15. Dans AL, Dans LF, Guyatt GH, Richardson S (1998) Users' guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. JAMA 279: 545-549.
16. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368: 987-998.
17. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman Jr OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005.
18. Derogar M, Sadr-Azodi O, Johar A, Lagergren P, Lagergren J (2013) Hospital and surgeon volume in relation to survival after esophageal cancer surgery in a population-based study. J Clin Oncol 31: 551-557.
19. Devesa SS, Blot WJ, Fraumeni Jr. JF (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83: 2049-2053.
20. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH (2000) The uncertainty principle and industrysponsored research. Lancet 356: 635-638.
21. Faivre J, Lemmens VE, Quipourt V, Bouvier AM (2007) Management and survival of colorectal cancer in the elderly in population-based studies. Eur J Cancer 43: 2279-2284.
22. Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, Storm H, Hall P, Holowaty E, Andersen A, Joensuu H, Andersson M, Kaijser M, Gospodarowicz M, Cohen R, Pukkala E, Travis LB (2007) Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99: 533-544.
23. Goodwin PJ, Ballman KV, Small EJ, Cannistra SA (2013) Evaluation of treatment benefit in journal of clinical oncology. J Clin Oncol 31: 1123-1124.
24. Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann VR, Neugut AI (2005) Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23: 6639-6646.
25. Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI (2006) Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 99: 313-321.
26. Hershman DL, Wright JD (2012) Comparative effectiveness research in oncology methodology: observational data. J Clin Oncol 30: 4215-4222.
27. Hutchins LF, Unger JM, Crowley JJ, Coltman Jr CA, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancertreatment trials. N Engl J Med 341: 2061-2067.
28. Johnson PM, Porter GA, Ricciardi R, Baxter NN (2006) Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 24: 3570-3575.
29. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551.
30. Kankesan J, Shepherd FA, Peng Y, Darling G, Li G, Kong W, Mackillop WJ, Booth CM (2013) Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based study. Curr Oncol 20: 30-37.
31. Kay A, Higgins J, Day AG, Meyer RM, Booth CM (2012) Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. Ann Oncol 23: 1646-1651.
32. Keating NL, O'Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448-4456.
33. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, Van de Poll-Franse LV, Haak HR (2013) Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 49(11): 2579-2586.
34. Krzyzanowska MK, Pintilie M, Tannock IF (2003) Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 290: 495-501.
35. Landrum MB, Keating NL, Lamont EB, Bozeman SR, McNeil BJ (2012) Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration. Cancer 118: 3345-3355.
36. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21: 1383-1389.
37. Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, Olivotto IA (2006) Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 24: 4888-4894.
38. Mackillop WJ (2007) Health services research in radiation oncology: toward achieving the achievable. In Clinical Radiation Oncology, Gunderson LL, Tepper JE (eds) pp 215-237. Churchill Livingstone: Philadelphia.
39. Mackillop WJ, Groome PA, Zhang-Solomons J, Zhou Y, Feldman-Stewart D, Paszat L, Dixon P, Holowaty EJ, Cummings BJ (1997) Does a centralized radiotherapy system provide adequate access to care? J Clin Oncol 15: 1261-1271.
40. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA (2003) The quality of health care delivered to adults in the United States. N Engl J Med 348: 2635-2645.
41. Meyer RM (2010) Generalizing the results of cancer clinical trials. J Clin Oncol 28: 187-189.
42. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 3239-3247.
43. Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, Amir E (2012) The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 30: 3012-3019.
44. Ohorodnyk P, Eisenhauer EA, Booth CM (2009) Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point? Eur J Cancer 45: 2249-2252.
45. Pearcey R, Miao Q, Kong W, Zhang-Salomons J, Mackillop WJ (2007) Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study. J Clin Oncol 25: 2383-2388.
46. Peppercorn J, Blood E, Winer E, Partridge A (2007) Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 109: 1239-1246.
47. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717.
48. Porter GA, Urquhart R, Bu J, Johnson P, Grunfeld E (2011) The impact of audit and feedback on nodal harvest in colorectal cancer. BMC Cancer 11: 2.
49. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29: 1252-1260.
50. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684.
51. Saltz LB (2008) Progress in cancer care: the hope, the hype, and the gap between reality and perception. J Clin Oncol 26: 5020-5021.
52. Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Sturmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D (2012) Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 104: 211-227.
53. Schreiber D, Rineer J, Weiss J, Leaf A, Karanikolas N, Rotman M, Schwartz D (2013) Characterization and outcomes of small cell carcinoma of the bladder using the surveillance, epidemiology, and end results database. Am J Clin Oncol 36: 126-131.
54. Seruga B, Hertz PC, Wang L, Booth CM, Cescon DW, Krzyzanowska M, Tannock IF (2010) Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. Ann Oncol 21: 1411-1418.
55. Seruga B, Sterling L, Wang L, Tannock IF (2011) Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 29: 174-185.
56. Tam VC, Tannock IF, Massey C, Rauw J, Krzyzanowska MK (2011) Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice. J Clin Oncol 29: 3133-3139.
57. Tyldesley S, Zhang-Salomons J, Groome PA, Zhou S, Schulze K, Paszat LF, Mackillop WJ (2000) Association between age and the utilization of radiotherapy in Ontario. Int J Radiat Oncol Biol Phys 47: 469-480.
58. Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, Crowley JJ (2013) Patient income level and cancer clinical trial participation. J Clin Oncol 31: 536-542.
59. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30: 3499-3506.
60. Vera-Badillo FE, Shapiro R, Ocana A, Amir E, Tannock IF (2013) Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol 24(5): 1238-1244.
61. Woolf SH, Johnson RE (2005) The break-even point: when medical advances are less important than improving the fidelity with which they are delivered. Ann Fam Med 3: 545-552.
62. Wu XC, Lund MJ, Kimmick GG, Richardson LC, Sabatino SA, Chen VW, Fleming ST, Morris CR, Huang B, Trentham-Dietz A, Lipscomb J (2012) Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 30: 142-150.